Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 914-916
10.1182/blood-2022-164600